← Back to home

UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Clinical trials for UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for Hard-to-Treat stomach cancer: drug combo trial launches

Disease control Recruiting now

This study tests a new combination of two drugs (iparomlimab and tuvonralimab, together called QL1706) plus chemotherapy in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The cancer must be HER2-negative and have …

Matched conditions: UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Phase: PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control

Last updated May 12, 2026 13:43 UTC

UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Get alerted when new UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear

New hope for Hard-to-Treat stomach cancer: drug combo trial launches